Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Caladrius Biosciences Inc (NASDAQ:CLBS)

1.44
Delayed Data
As of 1:18pm ET
 +0.0801 / +5.89%
Today’s Change
1.10
Today|||52-Week Range
7.22
-61.80%
Year-to-Date
SECTOR
Distribution Services
INDUSTRY
Wholesale Distributors
MARKET CAP
$75.3M

Company Description

Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. The companies business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that it leverages for the development of therapeutics while providing service to other companies in the cell therapy industry developing products. The company was founded in September 1980 and is headquartered in New York, NY.

Contact Information

Caladrius Biosciences, Inc.
420 Lexington Avenue
New York New York 10170
P:(212) 584-4180
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

David J. MazzoChief Executive Officer & Director
Robert S. VatersPresident, Chief Financial Officer & Director
Douglas W. LosordoChief Medical Officer & SVP-Regulatory Affairs
Robert A. PretiChief Scientific & Technology Officer
Joseph TalamoChief Accounting Officer, VP & Controller